Search clinical trials for: tetomilast (OPC-6535)

Total 978 results

Otsuka Pharmaceutical Co., Ltd.

Terminated

A Dose-finding Study of OPC-6535 in Patients With Active Crohn's Disease

Crohn Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Terminated

A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis

Colitis, Ulcerative

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

China, Japan, Korea, Republic of
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease

Crohn's Disease

Korea, Republic of, Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

Ulcerative Colitis

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

Ulcerative Colitis

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema (EMPHASIS)

Chronic Obstructive Pulmonary Disease

United States
Otsuka Pharmaceutical Co., Ltd.

Recruiting

A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])

Cardiac Edema (CHF)

Japan
Eye & ENT Hospital of Fudan University

Recruiting

An Observational Study of Clinical Treatments for Patients With Oropharyngeal Carcinoma

Oropharynx Carcinoma

China
Kyowa Kirin Co., Ltd.

Completed

A Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes Type 2

Japan
Otsuka Pharmaceutical Co., Ltd.

Recruiting

Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma (MM)

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term Trial of OPC-34712 in Patients With Schizophrenia

Schizophrenia

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Multicenter, Open-label, Safety and Tolerability Study (STEP 210)

Schizophrenia

United States, Bulgaria, Philippines, Romania, Russian Federation, Serbia, Croatia, India, Korea, Republic of, Slovakia, Taiwan, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia (ZENITH)

Schizophrenia

Korea, Republic of, United States, Philippines, Malaysia, Croatia, Serbia, Russian Federation, Ukraine, Romania, Puerto Rico, Colombia, Turkey, Poland, Taiwan, Canada, Latvia, Slovakia, Mexico, Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects

Schizophrenia | Psychiatric Disorders

United States
Kyowa Kirin Co., Ltd.

Completed

Along-term Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes, Type 2

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of OPC-262 in Patients With Type 2 Diabetes

Type 2 Diabetes

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects

Schizophrenia

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis

Pain Due to Osteoporosis

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes, Type 2

Japan
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712

Schizophrenia
Otsuka Pharmaceutical Development & Commercialization...
Bill and Melinda Gates Foundation

Completed

A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis

Pulmonary TB

South Africa
Otsuka Beijing Research Institute

Completed

OPC-61815 in Healthy Chinese Male Subjects

Healthy Adult Male

China
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870

Epilepsy

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia (BEACON)

Acute Schizophrenia

United States, Philippines, Taiwan, Russian Federation, Croatia, Colombia, Mexico, Slovakia
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema

Cirrhosis

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase I, Open-Label Trial to Assess the Absorption, Metabolism, and Excretion of (14C)-OPC-61815 in Healthy Male Japanese Subjects

Healthy Adult Male

United Kingdom
Otsuka Pharmaceutical Co., Ltd.

Completed

Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake

Congestive Heart Failure

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia

Schizophrenia

Japan
Dorothy Kessler

Completed

Creating Satisfying Engagement in Daily Life Through Coaching for People With Multiple Sclerosis

Quality of Life | Multiple Sclerosis

Canada
Ottawa Hospital Research Institute
University of Ottawa

Completed

Occupational Performance Coaching for Stroke Survivors

Stroke

Canada
Wake Forest University Health Sciences

Completed

Flavonoid Supplementation and Endothelial Function

Healthy
Otsuka Frankfurt Research Institute GmbH

Completed

Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis

Pulmonary Tuberculosis

South Africa
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2 Trial of OPC-64005 for Major Depressive Disorder

Major Depressive Disorder

Japan
St. Joseph's Hospital and Medical Center, Phoenix
Barrow Neurological Institute; Ivy Brain Tumor Center

Recruiting

Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) Participants With EGFR Alterations or Fusions

High Grade Glioma

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683

Tuberculosis, Multidrug-Resistant

Korea, Republic of, China, Estonia, Latvia, Peru, Philippines
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation (CADENCE 215)

Atrial Fibrillation | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation

United States, Italy, Germany, Netherlands, Spain, United Kingdom
Otsuka Pharmaceutical Co., Ltd.

Completed

Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure

Congestive Heart Failure

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission

Ulcerative Colitis

United States
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

Efficacy and Safety of HRS-7535 Tablets in Adults With Type 2 Diabetic Kidney Disease

Type 2 Diabetic Kidney Disease
Chiesi Farmaceutici S.p.A.

Completed

A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of "Nexthaler" Dry Powder Inhaler in COPD Patients (NEXThaler)

COPD

United Kingdom
Neurocrine Biosciences
Takeda

Completed

TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants

Depressive Disorder

United Kingdom
The Hong Kong Polytechnic University
University of Otago; Food and Health Bureau, Hong Kong; National Cheng Kung University

Recruiting

Occupational Performance Coaching With Parents of Young Children With Developmental Disability

Developmental Disability

Hong Kong
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

Pharmacokinetic and Safety Studies of HRS-7535 in Subjects With Moderate Renal Insufficiency and Healthy Subjects

Type 2 Diabetes
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

A Phase I Single- and Multiple- Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7535 in Healthy Subjects

Healthy Subjects
Otsuka Pharmaceutical Co., Ltd.

Completed

Dose-response Study of OPC-12759 Ophthalmic Suspension

Dry Eye Syndromes

Japan
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

Efficacy and Safety of HRS-7535 Tablets in Obese Subjects .

Overweight and Obesity
Alcon Research

Withdrawn

Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis

Bacterial Conjunctivitis
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis

Tuberculosis

Latvia, Lithuania
Kineta Inc.
Wellcome Trust

Completed

Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants

Healthy

Australia

Search clinical trials for: tetomilast (OPC-6535)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations